Probing PPIs

Which of the following is the mainstay of treatment for peptic ulcer disease?

What is the primary therapeutic agent for peptic ulcers?

Which of the following antacids should not be used in chronic renal failure patients?

Which of the following H2 receptor antagonists is known to have weak antiandrogenic side effects?

Which of the following H2 receptor antagonists was taken off the market due to contamination with a known carcinogen?

Which of the following proton pump inhibitors is available as a parenteral formulation for intravenous use?

Which of the following proton pump inhibitors is the S-enantiomer of omeprazole?

Which of the following is NOT a concern raised about the widespread use of antibiotics for H. pylori therapy?

What is the recommended duration for combination therapy for H. pylori?

Which of the following is NOT mentioned as one of the agents used frequently in H. pylori therapy?

Which class of agents inhibits gastric acid secretion via potassium competitive binding of the H+,K+-ATPase?

Which agent has been awarded Fast Track status by the FDA for the treatment of H. pylori in combination with antibiotics?

What is the most common toxicity noted with prostaglandin analogues?

Which drug should be avoided in patients with chronic renal insufficiency to prevent aluminum-induced neurotoxicity?

Which of the following is NOT a potential side effect of long-term use of PPIs?

What is the recommended administration time for PPIs, except for the immediate-release formulation of omeprazole?

Which of the following drugs may interact significantly with PPIs metabolized by the cytochrome P450 system?

What is the mechanism behind rebound gastric acid hypersecretion after discontinuation of PPIs?

Which of the following is a potential side effect of long-term use of PPIs?

What effect can PPIs have on the antiplatelet effect of clopidogrel?

What is the suggested approach for patients needing to take PPIs long term?

What is the potential advantage of pantoprazole over other PPIs?